

Supplement Figure 1




Figure 1. The distribution of genetic subtypes within pathological subgroups. A-D: Pie charts showing the distribution of molecular subgroup, termed EZB-like, N1-like, MCD-like and ST2-like(A), the distribution of pathological subgroups within genetic subtypes (B), the distribution of genetic subtypes within pathological subgroups (C), and the distribution of genetic subtypes and pathological subgroups in a DH/TH cohort (D).




Figure 2. A: Kaplan–Meier models of progress-free survival (PFS) in all patients. CART treatment represented the patients were treated with CAR T-cells. No CART treatment represented the patients were not treated with CAR T-cells. B: Kaplan–Meier models of overall survival (OS) in patients treated with CAR T-cells. C: Kaplan–Meier models of overall survival in patients carrying the TP53 mutation treated with CAR T-cells compared with those not treated with CAR T-cells. The overall survival was quantified from the diagnosis date until the cutoff date. D: Kaplan–Meier models of OS in EZB-like subgroup patients. F: Kaplan–Meier models of OS in MCD-like subgroup patients.